Response to "Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months".

MLA

Villani, Alessia, et al. “Response to ‘Efficacy of Sonidegib in Histologic Subtypes of Advanced Basal Cell Carcinoma: Results from the Final Analysis of the Randomized Phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) Trial at 42 Months.’” Journal of the American Academy of Dermatology, vol. 84, no. 6, June 2021, pp. e299–300. EBSCOhost, https://doi.org/10.1016/j.jaad.2021.02.074.

APA

Villani, A., Fabbrocini, G., Costa, C., & Scalvenzi, M. (2021). Response to “Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months.” Journal of the American Academy of Dermatology, 84(6), e299–e300. https://doi.org/10.1016/j.jaad.2021.02.074

Chicago

Villani, Alessia, Gabriella Fabbrocini, Claudia Costa, and Massimiliano Scalvenzi. 2021. “Response to ‘Efficacy of Sonidegib in Histologic Subtypes of Advanced Basal Cell Carcinoma: Results from the Final Analysis of the Randomized Phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) Trial at 42 Months.’” Journal of the American Academy of Dermatology 84 (6): e299–300. doi:10.1016/j.jaad.2021.02.074.